Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program

 
• By Sten Stovall

Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.

RSV
Phase II data suggest a single shot of MVABN RSV induces a broad potent immune response • Source: Shutterstock

More from Clinical Trials

More from R&D